Is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 still in force?

Yes — PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 is currently in force.

When did PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 take effect?

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 was first recorded in 2021.

How many sections does PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 have?

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 contains 2 sections.

Where can I read the official version of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021?

The official text of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 is published at lom.agc.gov.my.

/akn/my/act/pua/2021/332

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021

The full official text, structured for quick navigation. Copy any provision or jump straight to a section.

Open source PDF

Type: P.U. (A)
Status: In force
Enacted: 2021
Sections: 2

Quick answer

About this p.u. (a)

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 is Malaysia P.U. (A), cited as P.U. (A) 332 2021, currently marked in force and first recorded in 2021.

Opening note

Preamble

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [Akta 366], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut: Nama

Seksyen 1

Perintah ini bolehlah dinamakan Perintah Racun (Pindaan Senarai Racun) 2021.

Seksyen 2

Pindaan Jadual Pertama

(a)

dalam Senarai Racun—

(i)

di bawah “Alkaloids; the following: their salts, simple or complex; their quaternary compounds:”, dengan menggantikan butiran “Colchicine” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

P.U. (A) 332 3

Names

Bahagian I

Part I

Bahagian II

Part II

Exempt

Group A

Group B

Group C

Group D

“Colchicine

Veterinary preparations for food-producing animals

All preparations unless in Group A”;

(ii)

dengan memasukkan selepas butiran “Alogliptin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Alpelisib

All preparations”;

P.U. (A) 332 4

(iii)

dengan memasukkan selepas butiran “Alphadolone acetate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Alpha-Phenylacetoacetamide

(APAA)

All preparations”;

(iv)

dengan memasukkan selepas butiran “Alpha-Phenylacetoacetonitrile (APAAN)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Alpha-Pyrrolidinohexanophenone

(Alpha-PHP, PV-7)

All preparations”;

P.U. (A) 332 5

(v)

dengan memasukkan selepas butiran “2-Amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“N-[(2S)-1-Amino-3,3-

dimethyl-1-oxobutan-2-yl]-1-

(cyclohexylmethyl)-1H-indazole-3-carboxamide

(ADB-CHMINACA, MAB-CHMINACA) (DD)

All preparations

N-[(2S)-1-Amino-3,3-

dimethyl-1-oxobutan-2-yl]-1-

[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide

(ADB-FUBINACA) (DD)

All preparations”;

P.U. (A) 332 6

(vi)

dengan memasukkan selepas butiran

“N-[(2S)-1-Amino-3-methyl-1-oxobutan-2yl]-1-

(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“N-[(2S)-1-Amino-3-methyl-1-

oxobutan-2-yl]-1-[(4-

fluorophenyl)methyl]indazole-

3-carboxamide (AB-FUBINACA)

All preparations”;

(vii)

dengan memasukkan selepas butiran “Cabergoline” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Cabozantinib

All preparations”;

P.U. (A) 332 7

(viii)

dengan menggantikan butiran “Chlorpromazine” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Chlorpromazine

Veterinary preparations for food-producing animals

All preparations unless in Group A”;

(ix)

dengan menggantikan butiran “Clioquinol and other halogenated hydroxyquinoline compound” dengan butiran

“Clioquinol and other halogenated hydroxyquinoline compound except halquinol”;

P.U. (A) 332 8

(x)

dengan memasukkan selepas butiran “Cucurbitacin; its derivatives” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“1-(4-Cyanobutyl)-N-

(2-phenylpropan-

2yl)-1H-indazole-3-

carboxamide (CUMYL-

4CN-BINACA) (DD)

All preparations”;

(xi)

dengan memasukkan selepas butiran “Daclatasvir” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Dacomitinib

All preparations”;

P.U. (A) 332 9

(xii)

dengan menggantikan butiran “Dapsone” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Dapsone

Veterinary preparations for food-producing animals

All preparations unless in Group A”;

(xiii)

dengan memasukkan selepas butiran “Dimethoxybromoamphetamine (DOB) (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“2,5-Dimethoxy-4-

chloroamphetamine

(DOC) (DD)

All preparations”;

P.U. (A) 332 10

(xiv)

dengan memasukkan selepas butiran “Ectylurea” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Edoxaban

All preparations”;

(xv)

dengan memasukkan selepas butiran “N-Ethylamphetamine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“N-Ethylhexedrone

(NEH, Hexen, Ethyl-Hex)

All preparations”;

P.U. (A) 332 11

(xvi)

dengan memasukkan selepas butiran “N-ethyl MDA (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“N-Ethylnorpentylone

(Ephylone) (DD)

All preparations”;

(xvii)

dengan memasukkan selepas butiran “Etidronate disodium” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Etizolam

All preparations”;

P.U. (A) 332 12

(xviii)

dengan memasukkan selepas butiran “Fampridine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Favipiravir

All preparations”;

(xix)

dengan memasukkan selepas butiran “4-Fluoroamphetamine (4-FA) (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“2-{[1-(4-Fluorobutyl)-

1H-indazole-3-

carbonyl]amino}-3,3-

dimethylbutanoate (4-F-MDMB-BINACA, 4F-ADB,

4F-MDMB-BUTINACA)

All preparations”;

P.U. (A) 332 13

(xx)

dengan memasukkan selepas butiran “Halothane” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Halquinol

All preparations unless in

Group B

Veterinary preparations”;

(xxi)

dengan memasukkan selepas butiran “2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Methyl alpha-phenylacetoacetate

(MAPA)

All preparations”;

P.U. (A) 332 14

(xxii)

dengan memasukkan selepas butiran “Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl}amino)-3-

methylbutanoate (5F-AMB)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Methyl (2S)-2-{[1-(5- fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-

dimethylbutanoate (5F-MDMB-PICA)

All preparations

Methyl (2S)-2-({1-[(4-

fluorophenyl)methyl]-1H-indazole-3-

carbonyl}amino)-3-methylbutanoate

(FUB-AMB) (DD)

All preparations

3,4-MDP-2-P Methyl glycidate (PMK glycidate)

All preparations

3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)

All preparations”;

P.U. (A) 332 15

(xxiii)

dengan menggantikan butiran “Metronidazole” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Metronidazole

Veterinary preparations for food-producing animals

All preparations unless in Group A”;

(xxiv)

dengan menggantikan perkataan

“Monoclonal antibody;

includes the followings:”

dengan perkataan

“Monoclonal antibody; includes the following:”;

(xxv)

di bawah “Monoclonal antibody; includes the following:”—

(A)

dengan memasukkan selepas butiran “Evolocumab” butiran “Galcanezumab”; dan

(B)

dengan memasukkan selepas butiran “Pertuzumab” butiran “Polatuzumab vedotin”;

P.U. (A) 332 16

(xxvi)

di bawah “Narcotic substances; the following:”—

(A)

dengan memasukkan selepas butiran “(DD) Codoxime” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD) Crotonylfentanyl

All preparations”;

(B)

dengan memasukkan selepas butiran “(DD) 1-Cyclohexyl-4-(1,2–diphenylethyl)piperazine (MT-45)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD) Cyclopropylfentanyl

All preparations”;

P.U. (A) 332 17

(C)

dengan memasukkan selepas butiran “(DD) Methadone-Intermediate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD) Methoxyacetylfentanyl

All preparations”;

(D)

dengan memasukkan selepas butiran “(DD) Opium” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD) Orthofluorofentanyl

All preparations”;

P.U. (A) 332 18

(E)

dengan memasukkan selepas butiran “(DD) Oxymorphone” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD)

Parafluorobutyrylfentanyl

All preparations”;

dan

(F)

dengan memasukkan selepas butiran “(DD) Trimeperidine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD) Valerylfentanyl

All preparations”;

P.U. (A) 332 19

(xxvii)

dengan memasukkan selepas butiran “Omeprazole” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Omidenepag

All preparations”;

(xxviii)

dengan menggantikan butiran “Profafenone; its salts” dengan butiran “Propafenone; its salts”;

(xxix)

dengan memasukkan selepas butiran “Rufinamide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Rurioctocog alfa pegol

All preparations”;

P.U. (A) 332 20

(xxx)

dengan memasukkan selepas butiran “Umeclidinium” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Upadacitinib

All preparations”; dan

(xxxi)

dengan menggantikan butiran “Vancomycin” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Vancomycin

Veterinary preparations for food-producing animals

All preparations unless in Group A or Group D

Preparations for laboratory use”; dan

P.U. (A) 332 21

(b)

dalam Lampiran kepada Senarai Racun—

(i)

dalam senarai “Amoebicides:” —

(A)

dengan menggantikan butiran “Clioquinol and other halogenated hydroxyquinoline compounds” dengan butiran

“Clioquinol and other halogenated hydroxyquinoline compounds except halquinol”; dan

(B)

dengan memasukkan selepas butiran “Emetine” butiran “Halquinol”;

(ii)

dalam senarai “Analeptics and Central Stimulants:” —

(A)

dengan memasukkan sebelum butiran “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-

carboxamide

(AB-PINACA)

(DD)

”

butiran

“N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-

(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA, MAB-CHMINACA) (DD)”;

(B)

dengan memasukkan selepas butiran “Dimethoxybromoamphetamine (DOB) (DD)” butiran “2,5-Dimethoxy-4-

chloroamphetamine (DOC) (DD)”;

(C)

dengan memasukkan selepas butiran “N-Ethylamphetamine; its salts” butiran “N-Ethylhexedrone (NEH, Hexen,

Ethyl-Hex)”; dan

P.U. (A) 332 22

(D)

dengan memasukkan selepas butiran “N-Ethyl MDA (DD)” butiran “N-Ethylnorpentylone (Ephylone) (DD)”;

(iii)

dalam senarai “Analgesics including antipyretic and anti-inflammatory agents:” —

(A)

dengan memasukkan selepas butiran “Amidopyrine; its salts” butiran “N-[(2S)-1-Amino-3,3-dimethyl-1-

oxobutan-2-yl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide (ADB-FUBINACA) (DD)”; dan

(B)

dengan memasukkan selepas butiran “[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetrametylcyclopropyl)

methanone(XLR-11)” butiran “Galcanezumab”;

(iv)

dalam senarai “Antineoplastic agents and Immunosuppressants:”—

(A)

dengan memasukkan selepas butiran “Alemtuzumab” butiran “Alpelisib”;

(B)

dengan memasukkan selepas butiran “Cabazitaxel” butiran “Cabozantinib”;

(C)

dengan memasukkan selepas butiran “Dacliximab” butiran “Dacomitinib”;

(D)

dengan memasukkan selepas butiran “Pirfenidone” butiran “Polatuzumab vedotin”; dan

(E)

dengan memasukkan selepas butiran “Trofosfamide” butiran “Upadacitinib”;

P.U. (A) 332 23

(v)

dalam senarai “Antiviral agents:” dengan memasukkan selepas butiran “Famciclovir” butiran “Favipiravir”;

(vi)

dalam senarai “Cardio drugs:” dengan menggantikan butiran “Profafenone; its salts” dengan butiran “Propafenone;

its salts”;

(vii)

dalam senarai “Industrial and laboratory poisons:”—

(A)

dengan memasukkan selepas butiran “Acetyl chloride” butiran “Alpha-Phenylacetoacetamide (APAA)”; dan

(B)

dengan memasukkan selepas butiran “Lysergic acid; its salts” butiran berikut:

“Methyl alpha-phenylacetoacetate (MAPA)

3,4-MDP-2-P Methyl glycidate (PMK glycidate)

3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)”;

(viii)

dalam senarai “Narcotics:”—

(A)

dengan memasukkan selepas butiran “(DD) Codoxime” butiran “(DD) Crotonylfentanyl”;

P.U. (A) 332 24

(B)

dengan memasukkan selepas butiran “(DD) 1-Cyclohexyl-4-(1,2- diphenylethyl)piperazine (MT-45)” butiran

“(DD) Cyclopropylfentanyl”;

(C)

dengan memasukkan selepas butiran “(DD) Methadone-Intermediate” butiran “(DD) Methoxyacetylfentanyl”;

(D)

dengan memasukkan selepas butiran “(DD) Opium” butiran “(DD) Orthofluorofentanyl”;

(E)

dengan memasukkan selepas butiran “(DD) Oxymorphone” butiran “(DD) Parafluorobutyrylfentanyl”; dan

(F)

dengan memasukkan selepas butiran “(DD) Trimeperidine” butiran “(DD) Valerylfentanyl”;

(ix)

dalam senarai “Thrombolytics/Fibrinolytics:” dengan memasukkan selepas butiran “Drotrecogin alfa (Recombinant human activated Protein C)” butiran “Edoxaban”;

(x)

dalam senarai “Tranquillisers:” dengan memasukkan selepas butiran “Emylcamate” butiran “Etizolam”; dan

(xi)

dalam senarai “Miscellaneous:”—

(A)

dengan menggantikan butiran “Allergens (in test kits)” dengan butiran “Allergens”;

P.U. (A) 332 25

(B)

dengan memasukkan selepas butiran “Allergens” butiran “Alpha-Pyrrolidinohexanophenone (Alpha-PHP,

PV-7)”;

(C)

dengan memasukkan selepas butiran “Amino acids, unless specified elsewhere in the List” butiran “N-[(2S)-1-

Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl] indazole-3-carboxamide (AB-FUBINACA)”;

(D)

dengan memasukkan selepas butiran “Cucurbitacin; its derivaties” butiran “1-(4-Cyanobutyl)-N-(2-

phenylpropan-2yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) (DD)”;

(E)

dengan memasukkan selepas butiran “Fluorides, alkali; organofluorides” butiran “2-{[1-(4-Fluorobutyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (4-F-MDMB-BINACA, 4F-ADB, 4F-MDMB-BUTINACA)”;

(F)

dengan memasukkan selepas butiran “3,4 -Methylenedioxypyrovalerone (MDPV)” butiran berikut:

“Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PICA)

Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (FUB-AMB)

(DD)

”;

(G)

dengan memasukkan selepas butiran “Omalizumab” butiran “Omidenepag”; dan

P.U. (A) 332 26

(H)

dengan memasukkan selepas butiran “Rosuvastatin” butiran “Rurioctocog alfa pegol”.

Dibuat 6 Julai 2021

[KKM.R.600-1/1/56; PN(PU2)172/XIX]

DATO’ SRI DR. ADHAM BIN BABA

Menteri Kesihatan

P.U. (A) 332 27

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) ORDER 2021

Opening note

Preamble

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order: Citation 1. This order may be cited as the Poisons (Amendment of Poisons List) Order 2021. Amendment of First Schedule 2. The Poisons Act 1952 is amended in the First Schedule —

(a)

in the Poison List—

(i)

under “Alkaloids; the following: their salts, simple or complex; their quaternary compounds:”, by substituting for the item

"Colchicine" and the particulars relating to it the following item:

P.U. (A) 332 28

Names

Exempt

Group A

Group B

Group C

Group D

“Colchicine

Veterinary preparations for food-producing animals

All preparations unless in Group A”;

(ii)

by inserting after the item “Alogliptin” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Alpelisib

All preparations”;

P.U. (A) 332 29

(iii)

by inserting after the item “Alphadolone acetate” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Alpha-Phenylacetoacetamide

(APAA)

All preparations”;

(iv)

by inserting after the item “Alpha-Phenylacetoacetonitrile (APAAN)” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Alpha-Pyrrolidinohexanophenone

(Alpha-PHP, PV-7)

All preparations”;

P.U. (A) 332 30

(v)

by inserting after the item “2-Amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane (DD)” and the particulars relating to it the following items:

Names

Exempt

Group A

Group B

Group C

Group D

“N-[(2S)-1-Amino-3,3-

dimethyl-1-oxobutan-2-yl]-

(cyclohexylmethyl)-1H-indazole-3-carboxamide

(ADB-CHMINACA, MAB-CHMINACA) (DD)

All preparations

N-[(2S)-1-Amino-3,3-

dimethyl-1-oxobutan-2-yl]-

1-[(4-fluorophenyl) methyl]-

1H-indazole-3-carboxamide

(ADB-FUBINACA) (DD)

All preparations”;

P.U. (A) 332 31

(vi)

by inserting after the item

“N-[(2S)-1-Amino-3-methyl-1-oxobutan-2yl]-1-

(cyclohexylmethyl)-1H-indazole-3-

carboxamide (AB-CHMINACA) (DD)” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“N-[(2S)-1-Amino-3-methyl-1-

oxobutan-2-yl]-1-[(4-

fluorophenyl)methyl]indazole-

3-carboxamide (AB-FUBINACA)

All preparations”;

(vii)

by inserting after the item “Cabergoline” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Cabozantinib

All preparations”;

(viii)

by substituting for the item “Chlorpromazine" and the particulars relating to it the following item:

P.U. (A) 332 32

Names

Exempt

Group A

Group B

Group C

Group D

“Chlorpromazine

Veterinary preparations for food-producing animals

All preparations unless in Group A”;

(ix)

by substituting for the item "Clioquinol and other halogenated hydroxyquinoline compound" the item “Clioquinol and other halogenated hydroxyquinoline compound except halquinol”;

(x)

by inserting after the item “Cucurbitacin; its derivatives” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“1-(4-Cyanobutyl)-N-

(2-phenylpropan-

2yl)-1H-indazole-3-

carboxamide (CUMYL-

4CN-BINACA) (DD)

All preparations”;

P.U. (A) 332 33

(xi)

by inserting after the item “Daclatasvir” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Dacomitinib

All preparations”;

(xii)

by substituting for the item “Dapsone” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Dapsone

Veterinary preparations for food-producing animals

All preparations unless in Group A”;

P.U. (A) 332 34

(xiii)

by inserting after the item “Dimethoxybromoamphetamine (DOB) (DD)” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“2,5-Dimethoxy-4-

chloroamphetamine

(DOC) (DD)

All preparations”;

(xiv)

by inserting after the item “Ectylurea” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Edoxaban

All preparations”;

P.U. (A) 332 35

(xv)

by inserting after the item “N-Ethylamphetamine; its salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“N-Ethylhexedrone

(NEH, Hexen, Ethyl-Hex)

All preparations”;

(xvi)

by inserting after the item “N-ethyl MDA (DD)” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“N-Ethylnorpentylone

(Ephylone) (DD)

All preparations”;

P.U. (A) 332 36

(xvii)

by inserting after the item “Etidronate disodium” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Etizolam

All preparations”;

(xviii)

by inserting after the item “Fampridine” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Favipiravir

All preparations”;

(xix)

by inserting after the item “4-Fluoroamphetamine (4-FA) (DD)” and the particulars relating to it the following item:

P.U. (A) 332 37

Names

Exempt

Group A

Group B

Group C

Group D

“2-{[1-(4-Fluorobutyl)-

1H-indazole-3-

carbonyl]amino}-3,3-

dimethylbutanoate (4-F-MDMB-BINACA, 4F-ADB,

4F-MDMB-BUTINACA)

All preparations”;

(xx)

by inserting after the item “Halothane” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Halquinol

All preparations unless in Group B

Veterinary preparations”;

P.U. (A) 332 38

(xxi)

by inserting after the item “2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Methyl alpha-phenylacetoacetate

(MAPA)

All preparations”;

(xxii)

by inserting after the item “Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl}amino)-3- methylbutanoate (5F-AMB)” and the particulars relating to it the following items:

Names

Exempt

Group A

Group B

Group C

Group D

“Methyl (2S)-2-{[1-(5- fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-

dimethylbutanoate (5F-MDMB-PICA)

All preparations

P.U. (A) 332 39

Methyl (2S)-2-({1-[(4-

fluorophenyl)methyl]-1H-indazole-3-

carbonyl}amino)-3-methylbutanoate

(FUB-AMB) (DD)

All preparations

3,4-MDP-2-P Methyl glycidate (PMK glycidate)

All preparations

3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)

All preparations”;

(xxiii)

by substituting for the item “Metronidazole” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Metronidazole

Veterinary preparations for food-producing animals

All preparations unless in Group A”;

P.U. (A) 332 40

(xxiv)

by substituting for the words “Monoclonal antibody; includes the followings;” the words “Monoclonal antibody;

includes the following:”;

(xxv)

under “Monoclonal antibodies; includes the following:”—

(A)

by inserting after the item “Evolocumab” the item “Galcanezumab”; and

(B)

by inserting after the item “Pertuzumab” the item “Polatuzumab vedotin”;

(xxvi)

under “Narcotic substances; the following:”—

(A)

by inserting after the item “(DD) Codoxime” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD) Crotonylfentanyl

All preparations”;

(B)

by inserting after the item “(DD) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)” and the particulars relating to it the following item:

P.U. (A) 332 41

Names

Exempt

Group A

Group B

Group C

Group D

“(DD) Cyclopropylfentanyl

All preparations”;

(C)

by inserting after the item “(DD) Methadone-Intermediate” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD) Methoxyacetylfentanyl

All preparations”;

(D)

by inserting after the item “(DD) Opium” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD) Orthofluorofentanyl

All preparations”;

P.U. (A) 332 42

(E)

by inserting after the item “(DD) Oxymorphone” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD)

Parafluorobutyrylfentanyl

All preparations”;

and

(F)

by inserting after the item “(DD) Trimeperidine” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“(DD) Valerylfentanyl

All preparations”;

(xxvii)

by inserting after the item “Omeprazole” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Omidenepag

All preparations”;

P.U. (A) 332 43

(xxviii)

by substituting for the item “Profafenone; its salts” the item “Propafenone; its salts”;

(xxix)

by inserting after the item “Rufinamide” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Rurioctocog alfa pegol

All preparations”;

(xxx)

by inserting after the item “Umeclidinium” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Upadacitinib

All preparations”;

and

P.U. (A) 332 44

(xxxi)

by substituting for the item “Vancomycin” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Vancomycin

Veterinary preparations for food-producing animals

All preparations unless in Group A or Group D

Preparations for laboratory use”; and

(b)

in the Appendix to the Poisons List—

(i)

in the list of “Amoebicides:”—

(A)

by substituting for the item “Clioquinol and other halogenated hydroxyquinoline compounds” the item

“Clioquinol and other halogenated hydroxyquinoline compounds except halquinol”; and

(B)

by inserting after the item “Emetine” the item “Halquinol”;

(ii)

in the list of “Analeptics and Central Stimulants:”—

P.U. (A) 332 45

(A)

by inserting after the item “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-carboxamide

(AB-PINACA) (DD)” the item “N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-

(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA, MAB-CHMINACA) (DD)”;

(B)

by inserting after the item “Dimethoxybromoamphetamine (DOB) (DD)” the item “2,5-Dimethoxy-4-

chloroamphetamine (DOC) (DD)”;

(C)

by inserting after the item “N-Ethylamphetamine; its salts” the item “N-Ethylhexedrone (NEH, Hexen, Ethyl-Hex)”; and

(D)

by inserting after the item “N-Ethyl MDA (DD)” the item “N-Ethylnorpentylone (Ephylone) (DD)”;

(iii)

in the list of “Analgesics including antipyretic and anti-inflammatory agents:”—

(A)

by inserting after the item “Amidopyrine; its salts” the item “N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-

[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide (ADB-FUBINACA) (DD)”; and

(B)

by inserting after the item “[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetrametylcyclopropyl) methanone(XLR-

11)” the item “Galcanezumab”;

P.U. (A) 332 46

(iv)

in the list of “Antineoplastic agents and Immunosuppressants:”—

(A)

by inserting after the item “Alemtuzumab” the item “Alpelisib”;

(B)

by inserting after the item “Cabazitaxel” the item “Cabozantinib”;

(C)

by inserting after the item “Dacliximab” the item “Dacomitinib”;

(D)

by inserting after the item “Pirfenidone” the item “Polatuzumab vedotin”; and

(E)

by inserting after the item “Trofosfamide” the item “Upadacitinib”;

(v)

in the list of “Antiviral agents:” by inserting after the item “Famciclovir” the item “Favipiravir”;

(vi)

in the list of “Cardio drugs:” by substituting for the item “Profafenone; it salts” the item “Propafenone; it salts”;

(vii)

in the list of “Industrial and laboratory poisons:” —

(A)

by inserting after the item “Acetyl chloride” the item “Alpha-Phenylacetoacetamide (APAA)”; and

P.U. (A) 332 47

(B)

by inserting after the item “Lysergic acid; its salts” the following items:

“Methyl alpha-phenylacetoacetate (MAPA)

3,4-MDP-2-P Methyl glycidate (PMK glycidate)

3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)”;

(viii)

in the list of “Narcotics:” —

(A)

by inserting after the item “(DD) Codoxime” the item “(DD) Crotonylfentanyl”;

(B)

by inserting after the item “(DD) 1-Cyclohexyl-4-(1,2- diphenylethyl)piperazine (MT-45)” the item

“(DD) Cyclopropylfentanyl”;

(C)

by inserting after the item “(DD) Methadone-Intermediate” the item “(DD) Methoxyacetylfentanyl”;

(D)

by inserting after the item “(DD) Opium” the item “(DD) Orthofluorofentanyl”;

(E)

by inserting after the item “(DD) Oxymorphone” the item “(DD) Parafluorobutyrylfentanyl”; and

P.U. (A) 332 48

(F)

by inserting after the item “(DD) Trimeperidine” the item “(DD) Valerylfentanyl”;

(ix)

in the list of “Thrombolytics/Fibrinolytics:”, by inserting after the item “Drotrecogin alfa (Recombinant human activated Protein C)” the item “Edoxaban”;

(x)

in the list of “Tranquillisers:” by inserting after the item “Emylcamate” the item “Etizolam”; and

(xi)

in the list of “Miscellaneous:”—

(A)

by substituting for the item “Allergens (in test kits)” the item “Allergens”;

(B)

by inserting after the item “Allergens” the item “Alpha-Pyrrolidinohexanophenone (Alpha-PHP, PV-7)”;

(C)

by inserting after the item “Amino acids, unless specified elsewhere in the List” the item “N-[(2S)-1-Amino-3-

methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide (AB-FUBINACA)”;

(D)

by inserting after the item “Cucurbitacin; its derivatives” the item “1-(4-Cyanobutyl)-N-(2-phenylpropan-2yl)-

1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) (DD)”;

(E)

by inserting after the item “Fluorides, alkali; organofluorides” the item “2-{[1-(4-Fluorobutyl)-1H-indazole-3-

carbonyl]amino}-3,3-dimethylbutanoate (4-F-MDMB-BINACA, 4F-ADB, 4F-MDMB-BUTINACA)”;

P.U. (A) 332 49

(F)

by inserting after the item “3,4 -Methylenedioxypyrovalerone (MDPV)” the following items:

“Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PICA)

Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (FUB-AMB)

(DD)

”;

(G)

by inserting after the item “Omalizumab” the item “Omidenepag”; and

(H)

by inserting after the item “Rosuvastatin” the item “Rurioctocog alfa pegol”.

Made 6 July 2021

[KKM.R.600-1/1/56; PN(PU2)172/XIX]

DATO’ SRI DR. ADHAM BIN BABA

Minister of Health

Common questions

What is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021?: PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 is Malaysia P.U. (A), cited as P.U. (A) 332 2021, currently marked in force and first recorded in 2021.
Is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 still in force?: Yes — PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 is currently in force.
When did PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 take effect?: PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 was first recorded in 2021.
How many sections does PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 have?: PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 contains 2 sections.
Where can I read the official version of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021?: The official text of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021 is published at lom.agc.gov.my.